The ascendancy of Viagra and its impact on the medicinal landscape presents a complicated question for shareholders. While the early sales figures were impressive, the patent has expired, leading to a flood of generic alternatives that are reducing earnings. Furthermore, the sector is facing difficulties related to demographic trends and changin… Read More